Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 49, Issue 7, 2008, Pages 1246-1254

  Thomas, Xavier ^a   Dombret, Hervé ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Allogeneic stem cell transplantation; Bcr Abl; Philadelphia chromosome; Treatment; Tyrosine kinase inhibitors

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ADAPHOSTIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CGX 635; CYCLOPHOSPHAMIDE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; FINGOLIMOD; HOMOHARRINGTONINE; IMATINIB; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; UNINDEXED DRUG; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 47649121520     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801993504     Document Type: Review

References (84)

1. Schlieben, S., Borkhardt, A., Reinisch, I., Ritterbach, J., Janssen, J. W. Ratei, R. et al. (1996) Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia, 10, pp. 957-963.
2. Groupe Français de Cytogénétique Hématologique (1996) Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings and outcome. Blood, 87, pp. 3135-3142.
3. Radich, J. P. (2001) Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am, 15, pp. 21-36.
4. Bartram, C. R., de Klein, A., Hagemeijer, A., Van Agthoven, T., Geurts Van Kessal, A HM Bootsma, D. et al. (1983) Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 306, pp. 277-280.
5. Chan, L. C., Karhi, K. K., Rayter, S. I., Heisterkamp, N., Eridani, S. Powles, R. et al. (1987) A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature, 325, pp. 635-637.
6. Maurer, J., Janssen, J WG, Thiel, E., Van Denderen, J., Ludwig, W. D. Aydemir, U. et al. (1991) Detection of chimeric Bcr-Abl genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet, 337, pp. 1055-1058.
7. Lugo, T. G., Pendergast, A. M., Muler, A. J. and Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science, 247, pp. 1079-1083.
8. Dombret, H., Gabert, J., Boiron, J. M., Rigal-Huguet, F., Blaise, D. Thomas, X. et al. (2002) Outcome of treatment in adults with Philadelphia chromosome-positive leukemia - results of the prospective multicenter LALA-94 trial. Blood, 100, pp. 2357-2366.
9. Gleissner, B., Gokbuget, N., Bartram, C. R., Janssen, B., Rieder, H. Janssen, J WG et al. (2002) Leading prognostic relevance of the Bcr-Abl translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood, 99, pp. 1536-1543.
10. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. and Kantarjian, H. M. (1999) The biology of chronic myeloid leukemia. N Engl J Med, 341, pp. 164-172.
11. Rieder, H., Ludwig, W. D., Gassmann, W., Maurer, J., Janssen, J WG Gokbuget, N. et al. (1996) Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol, 95, pp. 678-691.
12. Secker-Walker, L. M., Prentice, H. G., Durrant, J., Richards, S., Hall, E. and Harrison, G. (1997) Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukemia on MRC trail UKALL XA. Br J Haematol, 96, pp. 601-610.
13. Westbrook, C. A., Hooberman, A. L., Spino, C., Dodge, R. K., Larson, R. A. Davey, F. et al. (1992) Clinical significance of the Bcr-Abl fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762. Blood, 80, pp. 2983-2990.
14. Götz, G., Weh, H. J., Walter, T. A., Kuse, R., Kolbe, K. Dolken, G. et al. (1992) Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Haematol, 64, pp. 97-100.
15. Preti, H. A., O'Brien, S., Giralt, S., Beran, M., Pierce, S. and Kantarjian, H. M. (1994) Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients. Am J Med, 97, pp. 60-65.
16. Annino, L., Vegna, M. L., Camera, A., Specchia, G., Visani, G. Fioritoni, G. et al. (2002) Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 99, pp. 863-871.
17. Thomas, X., Thiebaut, A., Olteanu, N., Danaila, C., Charrin, C. Archimbaud, E. et al. (1998) Philadelphia chromosome positive adult acute lymphoblastic leukemia: Characteristics, prognostic factors and treament outcome. Hematol Cell Ther, 40, pp. 119-128.
18. Kantarjian, H. M., O'Brien, S., Smith, T. L., Cortes, J., Giles, F. J. Beran, M. et al. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol, 18, pp. 547-561.
19. Forman, S. J., O'Donnell, M. R., Nademanee, A. P., Snyder, D. S., Bierman, P. J. Schmidt, G. M. et al. (1987) Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 70, pp. 587-588.
20. Barrett, A. J., Horowitz, M. M., Ash, R. C., Atkinson, K., Gale, R. P. Goldman, J. M. et al. (1992) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 79, pp. 3067-3070.
21. Chao, N. J., Blume, K. G., Forman, S. J. and Snyder, D. S. (1995) Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 85, pp. 3353-3354.
22. Snyder, D. S., Nademanee, A. P., O'Donnell, M. R., Parker, P. M., Stein, A. S. Margolin, K. et al. (1999) Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia, 13, pp. 2053-2058.
23. Goldstone, A. H., Prentice, H. G., Durrant, J., Franklin, I. M., Harrison, G. Richards, S. M. et al. (2001) Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993. Blood, 98, p. 856a.
24. Martin, T. G. and Gajewski, J. L. (2001) Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am, 15, pp. 97-120.
25. Cornelissen, J. J., Carston, M., Kollman, C., King, R., Dekker, A. W. Löwenberg, B. et al. (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood, 97, pp. 1572-1577.
26. Yanada, M., Naoe, T., Iida, H., Sakamaki, H., Sakura, T. Kanamori, H. et al. (2005) Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: Significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant, 36, pp. 867-872.
27. Esperou, H., Boiron, J. M., Cayuela, J. M., Blanchet, O., Kuentz, M. Jouet, J. P. et al. (2003) A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant, 31, pp. 909-918.
28. Martin, H., Atta, J., Bruecher, J., Elsner, S., Schardt, C. Stadler, M. et al. (1994) In patients with Bcr-Abl-positive ALL in CR, peripheral blood contains less residual disease than bone marrow: Implications for autologous BMT. Ann Haematol, 68, pp. 85-87.
29. Houot, R., Tavernier, E., Le, Q. H., Lheritier, V., Thiebaut, A. and Thomas, X. (2004) Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: Prognostic factors and treatment outcome. Hematology, 9, pp. 369-376.
30. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M. Fanning, S. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2, pp. 561-566.
31. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S. Druker, B. J. et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 295, pp. 139-145.
32. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F. Ford, J. M. et al. (2001) Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 344, pp. 1038-1042.
33. Ottmann, O. G., Druker, B. J., Sawyers, C. L., Goldman, J. M., Reiffers, J. Silvert, R. T. et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100, pp. 1965-1971.
34. + ALL. Leukemia, 16, pp. 2358-2365.
35. Pfeifer, H., Wassmann, B., Hofmann, W. K., Komor, M., Scheuring, U. Bruck, P. et al. (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res, 9, pp. 4674-4681.
36. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R. Rao, P. N. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science, 293, pp. 876-880.
37. Avramis, I. A., Laug, W. E., Sausville, E. A., Laug, W. E., Gonzalez-Gomez, I. McNamara, G. et al. (2003) Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol, 52, pp. 307-318.
38. Thomas, D. A., Faderl, S., Cortes, J., O'Brien, S., Giles, F. J. Kornblau, S. M. et al. (2004) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood, 103, pp. 4396-4407.
39. Thomas, D. A., Kantarjian, H. M., Cortes, J., Faderl, S., Giles, F. Garcia-Manero, G. et al. (2006) Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL. Blood, 108, pp. 87a-88a.
40. Towatari, M., Yanada, M., Usui, N., Takeuchi, J., Sugiura, I. Takeuchi, M. et al. (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed Bcr-Abl-positive acute lymphoblastic leukemia. Blood, 104, pp. 3507-3512.
41. Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N. Yagasaki, F. et al. (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed Bcr-Abl-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol, 24, pp. 460-466.
42. + ALL. Blood, 108, pp. 1469-1477.
43. Fielding, A. K., Richards, S. M., Lazarus, H. M., Litzow, M. R., Luger, S. M. Marks, D. I. et al. (2007) Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. Blood, 110, p. 10a.
44. De Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F. Maury, S. et al. (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood, 109, pp. 1408-1413.
45. Lee, S., Kim, D. W., Kim, Y. J., Chung, N. G., Kim, Y. L. Hwang, J. Y. et al. (2003) Minimal residual disease-based role of imatinib as first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 102, pp. 3068-3070.
46. Lee, S., Kim, Y. J., Min, C. K., Kim, H. J., Eom, K. S. Kim, D. W. et al. (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 105, pp. 3449-3457.
47. + ALL. Blood, 106, pp. 458-463.
48. Anderlini, P., Sheth, S., Hicks, K., Ippoliti, C., Giralt, S. Champlin, R. E. et al. (2004) Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant, 10, pp. 883-884.
49. Carpenter, P. A., Snyder, D. S., Flowers, M. E., Sanders, J. E., Gooley, T. A. Martin, P. J. et al. (2007) Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood, 109, pp. 2791-2793.
50. Visani, G., Isidori, A., Malagola, M., Alberti, D., Capdeville, R. Martinelli, G. et al. (2002) Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: Long-term quantitative molecular remission in relapsed p190 Bcr-Abl positive acute lymphoblastic leukemia. Leukemia, 16, pp. 2159-2160.
51. + ALL). Leukemia, 17, pp. 1919-1924.
52. Rousselot, P., Recher, C., Buzyn, A., Witz, F., Vey, N. Escoffre-Barbe, M. et al. (2007) Results of the AFR07 prospective study in de novo Philadelphia positive ALL patients aged over 55 years: Efficacy and safety of a Glivec® based induction followed by maintenance therapy with Glivec® and Pegasys®. Blood, 110, pp. 828A-829A.
53. Delannoy, A., Delabesse, E., Lheritier, V., Castaigne, S., Rigal-Huguet, F. Raffoux, E. et al. (2006) Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study. Leukemia, 20, pp. 1526-1532.
54. Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondi, F Ferrara, F. et al. (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) LAL0201-B protocol. Blood, 109, pp. 3676-3678.
55. Ottmann, O. G., Wassmann, B., Pfeifer, H., Giagounidis, A., Stelljes, M. Duhrsen, U. et al. (2007) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL. Cancer, 109, pp. 2068-2076.
56. Pfeifer, H., Wassmann, B., Pavlova, A., Wunderle, L., Oldenburg, J. Binckebanck, A. et al. (2007) Kinase domain mutations of Bcr-Abl frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL. Blood, 110, pp. 727-734.
57. Thomas, J., Wang, L., Clark, R. E. and Pirmohamed, M. (2004) Active transport of imatinib into and out of cells: Implications for drug resistance. Blood, 104, pp. 3739-3745.
58. Hofmann, W. K., Komor, M., Hoelzer, D. and Ottmann, O. G. (2004) Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma, 45, pp. 655-660.
59. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R. Bcr-Abl, independence et al. (2003) LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101, pp. 690-698.
60. Von Bubnoff, N., Peschel, C. and Duyster, J. (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec. Leukemia, 17, pp. 829-838.
61. Blencke, S., Zech, B., Engkvisto, O., Greff, Z., Orfi, L. Horvath, Z. et al. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol, 11, pp. 691-701.
62. Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M. Fabbro, D. et al. (2004) Requirement of Src kinases Lyn, Hck and Fgr for Bcr-Abl1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet, 36, pp. 453-461.
63. Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. Sawyers, C. L. et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, pp. 399-401.
64. Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W. Ray, A. et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7, pp. 129-141.
65. Wild, R., Castaneda, S., Flefleh, C., Fager, K., Inigo, I. Kan, D. et al. (2004) BMS-354825, a dual SRC/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth. Blood, 104, p. 549a.
66. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J. Paquette, R. et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354, pp. 2531-2541.
67. Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F. Larson, R. A. et al. (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood, 110, pp. 2309-2315.
68. Porkka, K., Simonsson, B., Dombret, H., Martinelli, G., Ottmann, O. G. Zhu, C. et al. (2007) Efficacy of dasatinib in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib: 2-year follow-up data from START-L (CA180-015. Blood, 110, pp. 826A-827A.
69. Ravandi, F., Thomas, D., Kantarjian, H., Faderl, S., Koller, C. Brown, D. et al. (2007) Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or Bcr-Abl positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB. Blood, 110, p. 828A.
70. Foa, R., Vignetti, M., Vitale, A., Meloni, G., Guarini, A. De Propris, M. et al. (2007) Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: Interim analysis of the GIMEMA prospective study LAL1205. Blood, 110, p. 10a.
71. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S. Wassmann, B. et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354, pp. 2542-2551.
72. + ALL) who are resistant or intolerant to imatinib. Blood, 110, p. 828A.
73. +) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood, 110, p. 144a.
74. + ALL. Blood, 110, p. 146a.
75. Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Palandri, F. Giannoulia, P. et al. (2007) Philadelphia chromosome-positive leukemia patients who harbor imatinib-resistant mutations have a higher likelihood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors. Blood, 110, p. 101a.
76. Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O. Nakayama, T. et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med, 10, pp. 262-267.
77. Giles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H. and Freedman, S. J. (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I Bcr-Abl mutation. Blood, 109, pp. 500-502.
78. De Lavallade, H., Khorashad, J. S., Davis, H. P., Milojkovic, D., Kaeda, J. S. Goldman, J. M. et al. (2007) Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I Bcr-Abl mutation. Blood, 110, pp. 2779-2780.
79. Matsuoka, Y., Nagahara, Y., Ikekita, M. and Shinomiya, T. (2003) A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol, 138, pp. 1303-1312.
80. Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M. Blaser, B. W. et al. (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Invest, 117, pp. 2408-2421.
81. O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W. Mestan, J. et al. (2005) Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res, 11, pp. 6987-6993.
82. Hoover, R. R., Mahon, F. X., Melo, J. V. and Davey, G. O. (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100, pp. 1068-1071.
83. Ferrajoli, A., Wang, Y., O'Brien, S. M., Faderl, S. H., Harris, D. M. Van, Q. et al. (2007) The synthetic heat shock protein (hsp) 90 inhibitor EC141 induces degradation of the Bcr-Abl p190 protein and apoptosis of Philadelphia chromosome(Ph)-positive acute lymphoblastic leukemia (ALL) cells. Blood, 110, p. 819A.
84. Klejman, A., Rushen, L., Morrione, A., Slupianek, A. and Skorski, T. (2002) Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene.21, pp. 5868-5876.